Navigation Links
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
Date:1/5/2012

ating other immune system disorders. Phase 1 clinical studies in normal healthy volunteers began in the fourth quarter of 2011.

R333, Topical JAK/SYK Inhibitor

Discoid Lupus Erythematosus (DLE) is an autoimmune system disorder of the skin. Inflamed disk-shaped sores on the face, chest and scalp, which may result in scaring, swelling and hair loss, characterize DLE. This disorder has an acute phase, which research has connected to SYK kinase signaling within the immune cascade. There is also a chronic phase of the disorder due to the abundance of JAK signaling. The current treatment options available for discoid lupus are few and have toxicities that further limit their use. In December 2011, Rigel began a Phase 1 clinical trial of R333, a topical JAK/SYK inhibitor, which may be useful in treating both phases of this potentially disfiguring disorder.  

R343, Inhaled SYK Inhibitor

In addition to the above clinical programs, Rigel expects to initiate a Phase 2 trial with R343, an inhaled SYK inhibitor, for patients with allergic asthma in mid-2012. This multi-center, multiple dose, placebo controlled study is expected to include approximately 300 asthma patients.  R343 will be delivered directly into the lungs via a dry inhalation device. Rigel will share additional information about its plans for R343 in future announcements.

Fostamatinib, SYK Inhibitor

In the meantime, Rigel's collaborator on fostamatinib, AstraZeneca (AZ), has indicated that the Phase 3 studies in rheumatoid arthritis are continuing as planned. The first of the OSKIRA (Oral SYK Inhibition in Rheumatoid Arthritis) studies, OSKIRA-1, completed full enrollment in the fourth quarter of 2011. OSKIRA-1 is a 12-month clinical trial of approximately 900 patients studying two dosing regimens of fostamatinib compared to placebo in patients who are not achieving an ad
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present at Oppenheimer Annual Healthcare Conference
2. Rigel Announces Third Quarter 2011 Financial Results
3. Rigel to Present at Two Upcoming Investor Conferences
4. Rigel to Present at Wells Fargo Securities Healthcare Conference
5. Rigel to Present at Jefferies Global Healthcare Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel Announces Proposed Public Offering of Common Stock
8. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
9. Rigel Announces First Quarter Financial Results
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Rigel to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)...  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... (USPTO) has issued a key patent covering ImmunoCellular,s ... targeting six tumor antigens that are commonly expressed ... 8,871,211, which issued October 28, 2014, include methods ... cell composition comprising peptide epitopes of the six ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... DATA), a technology and services company focused on global ... NTT DATA signed a non-exclusive license to resell DATATRAK ... an existing value-added reseller of DATATRAK ONE™ and Enterprise ... its reach into China to deliver clinical trials with ...
... Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage ... tumor cancers, issued the following letter to Shareholders today: ... Dear Shareholder: As we near the mid-point ... for the year. I want to review the key ...
Cached Medicine Technology:NTT DATA Licenses DATATRAK ONE™ for China 2NTT DATA Licenses DATATRAK ONE™ for China 3OncoSec Medical Issues Letter to Shareholders 2OncoSec Medical Issues Letter to Shareholders 3OncoSec Medical Issues Letter to Shareholders 4OncoSec Medical Issues Letter to Shareholders 5
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Food ads have ... lessen that effect, according to a new study. It ... cartoons, with a commercial between each cartoon. Half the children ... half saw a commercial for French fries. After watching ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... By Mary Brophy Marcus HealthDay Reporter , ... therapy given shortly after a kidney transplant allows some patients ... from attacking the new organ, according to a small new ... transplants are common in the United States and while they ...
... who had been given DES, the first synthetic form of ... while in the womb (in utero) is associated with many ... pre-cancerous conditions. The results of this analysis, conducted by researchers ... Institutes of Health, and collaborators across the country, were published ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... Oct. 5 (HealthDay News) -- Women whose mothers were ... increased risk for fertility problems and cancer as they ... U.S. National Cancer Institute "illustrates that the effects of ... decades to be fully appreciated or recognized in humans," ...
Cached Medicine News:Health News:TV Ads Whet Kids' Appetite for Junk Food 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 2Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 3Health News:Stem Cell Therapy Might Help Kidney Transplant Patients 4Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Health Woes Still Strike Women Exposed to Banned Pregnancy Drug 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: